If the first three quarters of 2019 were dominated by pricing fears, the last saw a remarkable comeback for biopharma.
Available to download for free now, our annual preview takes a data-driven look at 2020. Uncover biopharma’s biggest growth drivers, and see where the money is flowing.
Genfit investors, who early next year will see the Resolve-It study yield data, digest further developments in the Nash space.
Celgene CVR holders have been desperate to find out whether JCAR017 is approvable. Yesterday at Ash they got their answer... kind of.
The first in-depth look Roche’s anti-CD20 bispecific, mosunetuzumab, reveals some very encouraging response rates, even in patients who failed Car-T therapy.
Data from Gilead's Atlas combination trial in Nash could point to a way forward, while Roche and Ionis are hoping to confirm earlier signals seen with a…
A recent technology deal with Notch points to a problem that all allogeneic cell therapy players might sooner or later have to tackle.
One of the company’s Xeljanz follow-ons is slowly emerging from stealth mode in atopic dermatitis.
Hiking the price of a drug before generics appear is a long-enshrined practice, a situation that applies to most of the products singled out by Icer.